BR0009835A - Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo que sofre, ou susceptìvel à hipercolesterolemia, e a diarréia, e, uso de um aglutinante de ácido da bile - Google Patents

Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo que sofre, ou susceptìvel à hipercolesterolemia, e a diarréia, e, uso de um aglutinante de ácido da bile

Info

Publication number
BR0009835A
BR0009835A BR0009835-3A BR0009835A BR0009835A BR 0009835 A BR0009835 A BR 0009835A BR 0009835 A BR0009835 A BR 0009835A BR 0009835 A BR0009835 A BR 0009835A
Authority
BR
Brazil
Prior art keywords
bile acid
diarrhea
acid binder
pharmaceutical formulation
hypercholesterolemia
Prior art date
Application number
BR0009835-3A
Other languages
English (en)
Inventor
Bertil Abrahamsson
Ann-Margret Lindqvist
Anna-Lena Ungell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0009835A publication Critical patent/BR0009835A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

"FORMULAçãO FARMACêUTICA, USO DA MESMA, MéTODOS PARA TRATAMENTO PROFILáTICO OU TERAPêUTICO DE UM INDIVìDUO QUE SOFRE, OU SUSCEPTìVEL A HIPERCOLESTEROLEMIA, E à DIARRéIA, E, USO DE UM AGLUTINANTE DE áCIDO DA BILE". Uma formulação farmacêutica oral que compreende um composto inibidor do transporte de ácido da bile ileal (composto inibidor de IBAT) e um veículo terapeuticamente aceitável caracterizado em que a formulação é designada para liberar o composto inibidor de IBAT no íleo. O composto inibidor de IBAT pode ser também administrado em combinação com um aglutinante de ácido da bile para minimizar os efeitos colaterais possíveis de terapia com composto inibidor de IBAT, tal como, por exemplo, diarréia. O aglutinante de ácido da bile pode ser formulado para liberação de cólon.
BR0009835-3A 1999-04-19 2000-04-19 Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo que sofre, ou susceptìvel à hipercolesterolemia, e a diarréia, e, uso de um aglutinante de ácido da bile BR0009835A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901387A SE9901387D0 (sv) 1999-04-19 1999-04-19 New pharmaceutical foromaulations
PCT/SE2000/000755 WO2000062810A1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport

Publications (1)

Publication Number Publication Date
BR0009835A true BR0009835A (pt) 2002-01-08

Family

ID=20415263

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009835-3A BR0009835A (pt) 1999-04-19 2000-04-19 Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo que sofre, ou susceptìvel à hipercolesterolemia, e a diarréia, e, uso de um aglutinante de ácido da bile

Country Status (27)

Country Link
EP (1) EP1173205B1 (pt)
JP (1) JP2002542208A (pt)
KR (1) KR20010108516A (pt)
CN (1) CN1348384A (pt)
AT (1) ATE296641T1 (pt)
AU (1) AU767425B2 (pt)
BR (1) BR0009835A (pt)
CA (1) CA2379105A1 (pt)
CZ (1) CZ20013743A3 (pt)
DE (1) DE60020551T2 (pt)
DK (1) DK1173205T3 (pt)
EE (1) EE04607B1 (pt)
ES (1) ES2241603T3 (pt)
HK (1) HK1042850A1 (pt)
HU (1) HUP0200793A3 (pt)
IL (1) IL145871A0 (pt)
IS (1) IS2161B (pt)
NO (1) NO20015063D0 (pt)
NZ (1) NZ514264A (pt)
PL (1) PL351186A1 (pt)
PT (1) PT1173205E (pt)
SE (1) SE9901387D0 (pt)
SI (1) SI1173205T1 (pt)
SK (1) SK15282001A3 (pt)
TR (1) TR200103033T2 (pt)
WO (1) WO2000062810A1 (pt)
ZA (1) ZA200108539B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
MXPA02009478A (es) * 2001-01-31 2003-03-10 Roehm Gmbh Forma medicinal de multiples particulas que comrpende por lo menos dos formas de bolitas recubiertas de diferente manera.
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
CN1582151A (zh) 2001-09-08 2005-02-16 阿斯特拉曾尼卡有限公司 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
EP2300045A1 (en) 2008-05-15 2011-03-30 Transmolecular, Inc. Treatment of metastatic tumors
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
WO2010062863A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Compositions containing satiogens and methods of use
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
CA2788824C (en) 2010-02-04 2019-03-12 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
CN103097403B (zh) 2010-05-11 2017-04-19 弗雷德哈钦森癌症研究中心 氯毒素变体、缀合物及其使用方法
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
SI2637668T1 (sl) 2010-11-08 2016-11-30 Albiero Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
CA2815698C (en) * 2010-11-08 2019-04-30 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EA029581B1 (ru) * 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита
CN107375932B (zh) * 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CN105189540A (zh) 2012-12-10 2015-12-23 弗莱德哈钦森癌症研究中心 含脂质运载蛋白融合伴侣
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN105362244A (zh) * 2015-11-26 2016-03-02 青岛海之源智能技术有限公司 考来烯胺缓释片及制备方法
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
CN110996915B (zh) 2017-08-09 2023-10-03 阿尔比里奥公司 考来烯胺丸粒、口服考来烯胺制剂及其用途
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
WO2019245449A1 (en) 2018-06-20 2019-12-26 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
WO2020161216A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AU2020218908A1 (en) 2019-02-06 2021-08-26 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
MX2021009622A (es) 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Metodos para tratar la colestasis.
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230338392A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
TW289020B (pt) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤

Also Published As

Publication number Publication date
EE04607B1 (et) 2006-04-17
ZA200108539B (en) 2003-01-17
DK1173205T3 (da) 2005-08-08
HK1042850A1 (en) 2002-08-30
DE60020551D1 (de) 2005-07-07
NO20015063L (no) 2001-10-18
SE9901387D0 (sv) 1999-04-19
EE200100545A (et) 2003-02-17
SI1173205T1 (en) 2005-10-31
HUP0200793A3 (en) 2004-07-28
IS6109A (is) 2001-10-16
IS2161B (is) 2006-11-15
HUP0200793A2 (hu) 2002-07-29
EP1173205B1 (en) 2005-06-01
PT1173205E (pt) 2005-10-31
ATE296641T1 (de) 2005-06-15
TR200103033T2 (tr) 2002-03-21
IL145871A0 (en) 2002-07-25
DE60020551T2 (de) 2006-03-23
CZ20013743A3 (cs) 2002-01-16
JP2002542208A (ja) 2002-12-10
ES2241603T3 (es) 2005-11-01
CA2379105A1 (en) 2000-10-26
AU4633500A (en) 2000-11-02
EP1173205A1 (en) 2002-01-23
KR20010108516A (ko) 2001-12-07
WO2000062810A1 (en) 2000-10-26
SK15282001A3 (sk) 2002-04-04
NO20015063D0 (no) 2001-10-18
PL351186A1 (en) 2003-03-24
CN1348384A (zh) 2002-05-08
NZ514264A (en) 2003-10-31
AU767425B2 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
BR0009835A (pt) Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo que sofre, ou susceptìvel à hipercolesterolemia, e a diarréia, e, uso de um aglutinante de ácido da bile
BR0107333A (pt) Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo sofrendo de, ou susceptìvel a, hipercolesterolemia e diarréia, e, uso de um aglutinante de ácidos biliares
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
MY119365A (en) Novel pharmaceutical combination
MXPA00013037A (es) Composicion estable para dosis oral de liberacion extendida.
HUP0001162A2 (hu) Pirrolo-benzodiazepin-, -kinoxalin-, -pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények
HRP20070188B1 (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
BR9808422A (pt) Composto, composição farmacêutica, processos para induzir paralisia neuromuscular em um mamìfero e para a preparação de um composto, e, uso de um composto
ATE282418T1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
KR970061244A (ko) 치매 치료용 약학 조성물
TW349865B (en) Therapeutic agent for hemorrhoidal diseases
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
ATE22879T1 (de) Pharmazeutische zusammensetzungen und verfahren zu deren herstellung.
ATE253369T1 (de) Phosphatidylcholin als arzneimittel mit schleimhautschützender wirkung
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
TR199901958T2 (xx) �nfertiliteye kar�� ve fertiliteyi art�rmak i�in bir ila�.
DK0648117T3 (da) Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser
DK0692963T3 (da) Anvendelse af terbinafin til terapeutisk behandling af pneumocystose
BR0016654A (pt) Composto, método para o tratamento da dor, e, composição farmacêutica
BR0300434A (pt) Composição farmacêutica oral, utilizada como antiespasmódico geral do músculo liso com aplicações biliares, digestivas, urinárias e ginecológicas, e no tratamento da cólica intestinal moderada a severa, e, uso da mesma
Breivik et al. Relief of postoperative pain with zomepirac, paracetamol with codeine, or placebo
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.